SPG50（痙攣性截癱 50）的全球市場：依治療類型、給藥途徑、最終使用者和地區

SPG50（痙攣性截癱50）的全球市場規模預計2023年為1.3億美元，2031年達到2.863億美元，2024年至2031年年複合成長率為10.4%。

圖 1. SPG50（痙攣性截癱 50）的全球市場佔有率（%），按地區分類，2024 年

SPG50（痙攣性截癱50）是一種罕見的遺傳性神經系統疾病，其特徵是下肢痙攣和無力。它是由 CYTH4 基因突變引起的，該基因編碼 thylysin-4 蛋白，對於中樞神經系統軸突髓鞘形成至關重要。缺乏適當的髓鞘形成會影響大腦和下肢之間的運動神經訊號，導致僵硬和運動障礙。目前，尚無針對 SPG50 的核准治療方法，但基因和細胞療法的研究和開發有望在未來恢復髓鞘形成。

市場動態：.

SPG50（痙攣性截癱 50）的全球市場受到罕見遺傳病患病率上升、對罕見適應症的認知不斷提高以及為開發新治療方法活性化。然而，開發孤兒疾病藥物的高成本是一項重大挑戰。此外，監管核准時間長和病患數量少等市場限制也會影響該產品的商業性可行性。也就是說，政府以研究津貼、對藥物開發商的稅收優惠以及孤兒藥等指定項目的形式增加支持，為該行業增加投資提供了機會。

本研究的主要特點

• 本報告對SPG50（痙攣性截癱50）的全球市場進行了詳細分析，並列出了以2023年為基準年的預測期（2024-2031年）的市場規模和年複合成長率（CAGR%）。 。
• 它還說明了各個細分市場的潛在商機，並為該市場提供了一系列有吸引力的投資提案。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
• 它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球 SPG50（痙攣性截癱 50）市場的主要企業。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• SPG50（痙攣性截癱 50）的全球市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 透過用於分析全球 SPG50（痙攣性截癱 50）市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章 市場動態、法規與趨勢分析

• 市場動態
• 主要亮點
• 監管場景
• 最近的趨勢
• PEST分析
• 波特的分析
• 管道概覽
• 市場相關人員的投資場景
• 合併、收購和合作

第4章全球 SPG50（痙攣性截癱 50）市場 - 冠狀病毒（COVID-19）大流行的影響

• 新型冠狀病毒感染疾病（COVID-19）的流行病學
• 經濟影響

第5章全球SPG50（痙攣性截癱50）市場，依治療型，2019-2031

• 藥品
• 物理治療
• 外科手術
• 輔助設備
• 其他

第 6 章全球SPG50（痙攣性截癱 50）市場，依給藥途徑，2019-2031 年

• 口服
• 注射
• 外用
• 其他

第 7 章全球SPG50（痙攣性截癱 50）市場，依最終使用者分類，2019-2031 年

• 醫院和診所
• 復健中心
• 居家照護環境

第8章全球SPG50（痙攣性截癱50）市場，依地區，2019-2031

• 北美洲
• 美國
• 加拿大
• 歐洲
• 德國
• 英國
• 西班牙
• 法國
• 義大利
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 中國
• 印度
• 日本
• 澳洲
• 韓國
• ASEAN
• 其他亞太地區
• 拉丁美洲
• 巴西
• 阿根廷
• 墨西哥
• 其他拉丁美洲
• 中東
• 海灣合作理事會國家
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中部非洲
• 南非

第9章 競爭格局

• 公司簡介
  • Pfizer
  • Sanofi
  • Novartis
  • GlaxoSmithKline
  • Johnson &Johnson
  • Merck
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Amgen
  • Biogen
  • Takeda Pharmaceutical
  • AbbVie
  • Bristol-Myers Squibb
  • Astellas Pharma
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • Novo Nordisk

第10章

• 參考
• 調查方法
• 關於出版商

The global spastic paraplegia 50 market was valued at US$ 130 Mn in 2023 and is expected to reach US$ 286.3 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.

Figure 1. Global Spastic Paraplegia 50 Market Share (%), By Region, 2024

Spastic Paraplegia 50 (SPG50) is a rare genetic neurological disorder characterized by lower limb spasticity and weakness. It is caused by mutations in the CYTH4 gene, which encodes the cylicin-4 protein essential for myelination of axons in the central nervous system. Lack of proper myelination affects motor nerve signals between the brain and lower limbs, resulting in stiffness and impaired mobility. Currently, there is no approved treatment for SPG50; however, research into the development of gene and cell therapies holds promise to restore myelination in the future.

Market Dynamics:

The global spastic paraplegia 50 market is driven by the rising prevalence of rare genetic disorders, growing awareness about orphan indications, and increasing research focus on developing novel treatments. However, the high costs associated with orphan drug development pose a major challenge. The market also faces restraints from long regulatory approval timelines and a small patient pool, affecting the commercial viability of products. Nonetheless, increasing government support in the form of research grants, tax incentives for drug developers, and designation programs such as orphan drug status present lucrative opportunities for greater investment in this space.

Key features of the study:

• This report provides in-depth analysis of the global spastic paraplegia 50 market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global spastic paraplegia 50 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Pfizer, Sanofi, Novartis, GlaxoSmithKline, Johnson & Johnson, Merck, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, Biogen, Takeda Pharmaceutical, AbbVie, Bristol-Myers Squibb, Astellas Pharma, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, and Novo Nordisk.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global spastic paraplegia 50 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global spastic paraplegia 50 market.

Detailed Segmentation:

• Global Spastic Paraplegia 50 Market, By Treatment Type
  • Medication
  • Physiotherapy
  • Surgery
  • Assistive Devices
  • Others
• Global Spastic Paraplegia 50 Market, By Route of Administration
  • Oral
  • Injectable
  • Topical
  • Others
• Global Spastic Paraplegia 50 Market, By End User
  • Hospitals & Clinics
  • Rehab Centers
  • Home Care Settings
• Global Spastic Paraplegia 50 Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Top Companies in the Global Spastic Paraplegia 50 Market:
  • Pfizer
  • Sanofi
  • Novartis
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Amgen
  • Biogen
  • Takeda Pharmaceutical
  • AbbVie
  • Bristol-Myers Squibb
  • Astellas Pharma
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • Novo Nordisk

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Spastic Paraplegia 50 Market, By Treatment Type
  • Spastic Paraplegia 50 Market, By Route Of Administration
  • Spastic Paraplegia 50 Market, By End User
  • Spastic Paraplegia 50 Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restrains
  • Opportunities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• PEST Analysis
• PORTER's Analysis
• Pipeline Overview
• Investment Scenario by Market Players
• Mergers, Acquisitions, and Collaborations

4. Global Spastic Paraplegia 50 Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Economic Impact

5. Global Spastic Paraplegia 50 Market, By Treatment Type, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Medication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Physiotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Surgery
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Assistive Devices
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

6. Global Spastic Paraplegia 50 Market, By Route Of Administration, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

7. Global Spastic Paraplegia 50 Market, By End User, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospitals & Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Rehab Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
• Home Care Settings
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)

8. Global Spastic Paraplegia 50 Market, By Region, 2019-2031, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019 -2031
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• U.S.
• Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
• GCC Countries
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2019-2031,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
• North Africa
• Central Africa
• South Africa

9. Competitive Landscape

• Company Profile
  • Pfizer
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sanofi
  • Novartis
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Amgen
  • Biogen
  • Takeda Pharmaceutical
  • AbbVie
  • Bristol-Myers Squibb
  • Astellas Pharma
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • Novo Nordisk
• Analyst Views

10. Section

• References
• Research Methodology
• About us